Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performance-A LEA Study.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
02 2019
Historique:
received: 16 03 2018
revised: 05 09 2018
accepted: 14 09 2018
pubmed: 18 11 2018
medline: 2 11 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

To evaluate the association between medical and social environmental factors and the risk of repeating a grade in childhood leukemia survivors. A cross-sectional study of childhood leukemia survivors, recruited through the LEA cohort (Leucémie de l'Enfant et de l'Adolescent [French Childhood Cancer Survivor Study for Leukemia]) in 2014. An adjusted logistic regression model was used to identify variables linked to repeating a grade after the diagnosis among the survivors, and the rates of repeating a grade were compared between the survivors and their siblings using a multilevel logistic regression model. The mean age at inclusion of the 855 participants was 16.2 ± 7.0 years, and the mean duration of follow-up from diagnosis to evaluation was 10.2 ± 6.2 years. After disease onset, 244 patients (28.5%) repeated a grade, with a median interval of 4 years (IQR, 2-8 years). Independent factors associated with repeating a grade were male sex (OR, 1.78; 95% CI, 1.21-2.60), adolescence (OR, 2.70; 95% CI, 1.63-4.48), educational support during the treatment period (OR, 3.79; 95% CI, 2.45-5.88), low parental education level (OR, 2.493; 95% CI, 1.657-3.750), and household financial difficulties (OR, 2.62; 95% CI, 1.607-4.28). Compared with siblings, survivors were at greater risk of repeating a grade (OR, 1.87; 95% CI, 1.48-2.35). The most vulnerable patients seemed to be adolescents and those with parents of low socioeconomic status. Improving the schooling career of leukemia survivors will require that the medical community more carefully consider the social status of patients.

Identifiants

pubmed: 30442413
pii: S0022-3476(18)31377-5
doi: 10.1016/j.jpeds.2018.09.047
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-175.e2

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Jacinthe Bonneau (J)

Department of Pediatric Onco-Hematology, University Hospital of Rennes, Rennes1 University, Rennes, France. Electronic address: jacinthe.bonneau@chu-rennes.fr.

Julie Berbis (J)

Research Unit EA 3279 and Department of Public Health, Aix-Marseille University, Marseille, France.

Gerard Michel (G)

Research Unit EA 3279 and Department of Public Health, Aix-Marseille University, Marseille, France; Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, APHM and Aix-Marseille University, Marseille, France.

Camille Vercasson (C)

Research Unit EA 3279 and Department of Public Health, Aix-Marseille University, Marseille, France.

Yves Bertrand (Y)

Department of Pediatric Hematology, Institute of Pediatric Hematology and Oncology, Claude Bernard University Lyon, Paris, France.

Sophie Ansoborlo (S)

Department of Pediatric Onco-Hematology, University Hospital of Bordeaux, Bordeaux, France.

Jean-Hugues Dalle (JH)

Department of Pediatric Hematology, APHP, Robert Debre Hospital, Paris Diderot University, Paris, France.

Andre Baruchel (A)

Department of Pediatric Hematology, APHP, Robert Debre Hospital, Paris Diderot University, Paris, France.

Marie Dominique Tabone (MD)

Department of Paediatric Onco-Hematology, APHP, GHUEP, Trousseau La Roche-Guyon Hospital, Paris, France.

Catherine Paillard (C)

Department of Pediatric Onco-Hematology, University Hospital of Strasbourg, Strasbourg, France.

Audrey Contet (A)

Department of Pediatric Onco-Hematology, University Hospital of Nancy, Nancy, France.

Maryline Poirée (M)

Department of Pediatric Onco-Hematology, University Hospital of Nice, Nice, France.

Nicolas Sirvent (N)

Department of Pediatric Onco-Hematology, University Hospital of Montpellier, Montpellier, France.

Sandrine Thouvenin (S)

Department of Pediatric Onco-Hematology, University Hospital of Saint-Etienne, Saint-Etienne, France.

Justyna Kanold (J)

Department of Pediatric Onco-Hematology, CIC INSERM 501, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Claire Freycon (C)

Department of Pediatric Onco-Hematology, University Hospital of Grenoble, Grenoble, France.

Paul Saultier (P)

Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, APHM and Aix-Marseille University, Marseille, France.

Pascal Auquier (P)

Research Unit EA 3279 and Department of Public Health, Aix-Marseille University, Marseille, France.

Virginie Gandemer (V)

Department of Pediatric Onco-Hematology, University Hospital of Rennes, Rennes1 University, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH